Preparation and characterisation of nevirapine oral nanosuspensions

Indian Journal of Pharmaceutical Sciences

Volumn 76, Issue 1, 2014, Pages 62-71

  Raju, Anju ^a   Reddy, A ^b   Satheesh, J ^a   Jithan, A V ^a  

^a Mother Teresa College of Pharmacy   (India)

^b Hetero Drugs Limited   (India)

Author keywords

AIDS; In vitro drug release; Nanoedge method; Nanosuspension; Pharmacokinetic study; Polydispersibility index

Indexed keywords

CARBOXYMETHYLCELLULOSE; DICHLOROMETHANE; DODECYL SULFATE SODIUM; HYDROXYPROPYLMETHYLCELLULOSE; NEVIRAPINE; POLOXAMER; POLYSORBATE 80; POVIDONE; UNCLASSIFIED DRUG; VERAMUNE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MALE; MORPHOLOGY; NANOEDGE METHOD; NANOSUSPENSION; NONHUMAN; PARTICLE SIZE; PROCEDURES; RAT; SUSPENSION;

EID: 84898735435     PISSN: 0250474X     EISSN: 19983743     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Beg S, Swain S, Rizwan M, Irfnuddin M, Malini DS. Bioavailability enhancement strategies: Basics, formulation approaches and regulatory considerations. Curr Drug Deliv 2011;8:691-702.
2. Buckley ST, Frank KJ, Fricker G, Brandl M. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations". Eur J Pharm Sci 2013;50:8-16.
3. Chavhan SS, Petkar KC, Sawant KK. Nanosuspensions in drug delivery: Recent advances, patent scenarios, and commercialization aspects. Crit Rev Ther Drug 2011;28:447-88.
4. Raval AJ, Patel MJ. Preparation and characterization for solubility and dissolution rate enhancement of meloxicam. Int Res J Pharm Sci 2011;1:42-9.
5. Liu Y, Xie P, Zhang D, Zhang Q. A minireview of nanosuspensions development. J Drug Target 2012;20:209-23.
6. Ena J, Amador C, Benito C, Pasquau F. Pharmacological and clinical evidence of nevirapine immediate-and extended-release formulations. HIV AIDS (Auck) 2012;4:169-79.
7. Sarkar M, Perumal OP, Panchagnula R. Solid-state characterization of nevirapine. Indian J Pharm Sci 2008;70:619-30.
8. Kappelhoff BS, Huitema AD, van Leth F, Robinson PA, MacGregor TR, Lange JM, et al. Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study. HIV Clin Trials 2005;6:254-61. (Pubitemid 43025156)
9. Bogner JR. Nevirapine extended-release for the treatment of HIV-1 infection. Expert Rev Antiinfect Ther 2012;10:21-30.
10. Heil EL, Corbett AH. Guidelines for the use of extended-release nevirapine in HIV-injected patients. Exp Opin Pharmacother 2011;12:2713-8.
11. Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, et al. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-injected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). HIV Med 2012;13:236-44.
12. Grob PM, Wu JC, Cohen KA, Rngraham RH, Shih CK, Hargrave KD, et al. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: Nevirapine as a prototype drug. AIDS Res Hum Retroviruses 1992;8:145-52.
13. Kassem MA, Abdel Rahman AA, Ghorab MM, Ahmed MB, Khalil RM. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. Int J Pharm 2007;340:126-33. (Pubitemid 47043351)
14. Shegokar R, Singh KK. Nevirapine nanosuspensions for HIV reservoir targeting. Pharmazie 2011;66:408-15.
15. Tian X, Li H, Zhang D, Liu G, Jia L, Zheng D, et al. Nanosuspension for parenteral delivery of a p-terphenyl derivative: Preparation, characteristics and pharmacokinetic studies. Colloids Surf B Biointerfaces 2013;108:29-33.
16. Abdelbary AA, Li X, El-Nabarawi M, Elassasy A, Jasti B. Effect of fixed aqueous layer thickness of polymeric stabilizers on zeta potential and stability of aripiprazole nanosuspensions. Pharm Dev Technol 2013;18:730-5.
17. Pathak SM, Aggarwal D, Venkateswarlu V. Establishment of in vitro-in vivo equivalence of highly variable drugs-a generic product development perspective. Pharm Dev Technol 2014;19:401-10.
18. Singh AK. Evaluation of orlistat solid dispersion using poloxomer 188 as hydrophilic carrier. Sch Res J 2011;1:48-51.
19. Datta A, Ghosh NS, Ghosh S, Tapobana S, Samantha T, Das RC. Enhancement of solubility and dissolution profile of nevirapine by solid dispersion technique. Int J Chem Res 2011;2:53-8.
20. Lokamatha KM, Shanta Kumar SM, Rao NR. Enhancement of solubility and dissolution rate of nevirapine by solid dispersion technique using dextran: Preparation and in vitro evaluation. Dig J Nanomater Biostruct 2010;6:135-42.
21. Verma S, Gokhale R, Burgess DJ. A comparative study of top-down and bottom-up approaches for the preparation of micro/nanosuspensions. Int J Pharm 2009;380:216-22.
22. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: A promising drug delivery strategy. J Pharm Pharmacol 2004;56:827-40. (Pubitemid 38885975)
23. Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci 2011;3:426-34.
24. Howard SA, Mauger J, Hsieh JW, Amin K. Suspending agent effects on steroid suspension dissolution profiles. J Pharm Sci 1979;68:1475-9. (Pubitemid 10183425)
25. Sowjanya K, Shoba Deepthi K, Bharathi A. Formulation and evaluation of gastro-retentive floating matrix tablets of nevirapine. Int J Pharm Pharm Sci 2012;4:368-75.
26. Das SK, Roy S, Kalimuthu, Y, Khannam J, Nanda A. Solid dispersions: An approach to enhance the bioavailability of poorly water-soluble drugs. Int J Pharmacol Pharm Tech 2012;1:37-46.
27. Janssens S, Mooter GV. Review: physical chemistry of solid dispersions. J Pharm Pharmacol 2009;61:1571-86.
28. Jithan AV, Madhavi K, Madhavi M, Prabhakar K. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Investig 2011;1:119-25.
29. Pawar VK, Kansal S, Asthana S, Chourasia MK. Industrial perspective of gastroretentive drug delivery systems: Physicochemical, biopharmaceutical, technological and regulatory consideration. Expert Opin Drug Deliv 2012;9:551-65.
30. Caira MR, Bourne SA, Samsodien H, Engel E, Liebenberg W, Stieger N, et al. Co-crystals of the antiretroviral nevirapine: Crystal structures, thermal analysis and dissolution behavior. CrystEngComm 2012;14:2541-51.
31. Gajar PP, Kokil AA, Karekar PS, Gurav YA, Yadav AV. Improvement in physicochemical properties of nevirapine co-crystals. Int J Pharm Technol 2013;4:4831-42.
32. Werling J, Chaubal M, Kipp J, Rabinow B. Nanosuspensions of antiretroviral agents for increased central nervous system delivery. US Patent Application No. US200502002094.
33. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations and obstacles and their development. J Infect Dis 2011:204:669-74.